eli lilly trials retatrutide Phase 3 obesity trial results 2026 Eli Lilly's Retatrutide Delivers Record

Clinical trials involving over 900 human subjects across six randomized, double-blind, placebo-controlled studies confirmed the safety profile

Live animals

Overview Retatrutide is a synthetic, long-acting triple agonist that targets three distinct hormonal receptors: the glucagon-like pep-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR)

Effects of L-carnitine administration on VO2max and the aerobic-anaerobic threshold in normoxia and acute hypoxia

The studies were conducted using various mouse models to elucidate the role of RAMP1 and RAMP3 in mediating cagrilintides central and metabolic actions [2]

Chen J, Lou R, Zhou F, Li D, Peng C, Lin L